Oncolytics Biotech’s Promising Breast Cancer Study
Company Announcements

Oncolytics Biotech’s Promising Breast Cancer Study

Oncolytics Biotech (TSE:ONC) has released an update.

Oncolytics Biotech has announced positive results from its BRACELET-1 study for the pelareorep-based combination therapy in treating HR+/HER2- advanced or metastatic breast cancer, with significant improvements in overall survival rates and progression-free survival compared to chemotherapy alone. These findings bolster the company’s plans to secure funding for a pivotal registration-enabling study. The therapy’s potential was highlighted by the fact that over half of the patients treated with pelareorep were alive at the study’s conclusion, outperforming the control group.

For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyOncolytics announces key progress, upcoming studies
TheFlyOncolytics announces upcoming milestones
TipRanks Canadian Auto-Generated NewsdeskOncolytics Biotech’s Cancer Drug Aims for Fast-Track Approval
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App